DS
INBX icon

David Shaw’s Inhibrx INBX Stock Holding History

David Shaw’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Sell
22,322
-55,115
-71% -$5.52M ﹤0.01% 3151
2026
Q1 		$5.21M Sell
77,437
-44,664
-37% -$3.31M ﹤0.01% 2140
2025
Q4 		$9.65M Buy
122,101
+110,548
+957% +$7.53M 0.01% 1787
2025
Q3 		$389K Buy
+11,553
New +$284K ﹤0.01% 3988

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's INBX Position: Q2 2026 in Review

David Shaw reduced its Inhibrx (INBX) stake by 71% in Q2 2026, selling an estimated $5.52M and leaving 22,322 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

David Shaw first reported a position in INBX in Q3 2025 and has held it in 4 quarters since. The position peaked at $9.65M in Q4 2025. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • David Shaw held 22,322 shares of Inhibrx worth $2.12M as of Q2 2026.
  • David Shaw sold 55,115 Inhibrx shares in Q2 2026, an estimated $5.52M.
  • Inhibrx made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3151 holding.
  • David Shaw first reported a position in Inhibrx in Q3 2025 and has held it in 4 quarters since.
  • David Shaw's Inhibrx position peaked at $9.65M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.